Certolizumab Has Favorable Efficacy on Preventing Pancreas and Target Organs Damage in Acute Pancreatitis

• Published in: Pancreas Vol. 53; no. 7; p. e588
• Main Authors: Cirak, Zafer, Tanoglu, Alpaslan, Yeniceri, Murat, Tanoglu, Esra Guzel, Kaplan, Mustafa, Sade, Ayşe Gökcen
• Format: Journal Article
• Language: English
• Published: United States 01.08.2024
• Subjects: Acute Disease; Amylases - blood; Animals; Certolizumab Pegol - pharmacology; Disease Models, Animal; Glutathione Peroxidase - metabolism; Interleukin-1beta - blood; Interleukin-1beta - metabolism; Kidney - drug effects; Kidney - metabolism; Kidney - pathology; Liver - drug effects; Liver - metabolism; Liver - pathology; Lung - drug effects; Lung - metabolism; Lung - pathology; Male; Malondialdehyde - metabolism; Myocardium - metabolism; Myocardium - pathology; Oxidative Stress - drug effects; Pancreas - drug effects; Pancreas - metabolism; Pancreas - pathology; Pancreatitis - chemically induced; Pancreatitis - drug therapy; Pancreatitis - pathology; Pancreatitis - prevention & control; Rats; Rats, Sprague-Dawley; Superoxide Dismutase - metabolism; Transforming Growth Factor beta - metabolism; Tumor Necrosis Factor-alpha - blood; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 1536-4828
• DOI: 10.1097/MPA.0000000000002343

It was targeted to assess the efficacy of certolizumab on pancreas and target organs via biochemical parameters and histopathologic scores in experimental acute pancreatitis (AP). Forty male Sprague Dawley rats were divided into the following 5 equal groups: group 1 (sham group), group 2 (AP group), group 3 (AP + low-dose certolizumab group), group 4 (AP + high-dose certolizumab group), and group 5 (placebo group). Rats in all groups were sacrificed 24 hours after the last injection and amylase, tumor necrosis factor α, transforming growth factor β, interleukin 1β, malondialdehyde, superoxide dismutase, and glutathione peroxidase levels were studied in blood samples. Histopathological investigation of both the pancreas and target organs (lungs, liver, heart, kidneys) was performed by a pathologist blind to the groups. In silico analysis were also accomplished. The biochemical results in the certolizumab treatment groups were identified to be significantly favorable compared to the AP group (P < 0.001). The difference between the high-dose group (group 4) and low-dose treatment group (group 3) was found to be significant in terms of biochemical parameters and histopathological scores (P < 0.001). In terms of the effect of certolizumab treatment on the target organs (especially on lung tissue), the differences between the low-dose treatment group (group 3) and high-dose treatment group (group 4) with the AP group (group 2) were significant. Certolizumab has favorable protective effects on pancreas and target organs in AP. It may be a beneficial agent for AP treatment and may prevent target organ damage.